$SRPT confirms third patient death from gene therapy. Trial paused. FDA probes liver failure toll. Stock crashes 26%.
Sarepta Therapeutics is facing a third confirmed death tied to its experimental gene therapies. The company paused its Phase 1 trial for SRP-9004 on July 17, one day after internal documents revealed that a 51-year-old man had died from acute … Read more